| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 10/07/2004 | US20040198799 Methods of increasing endogenous testosterone levels |
| 10/07/2004 | US20040198781 Carbonic anhydrase inhibitor |
| 10/07/2004 | US20040198735 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents |
| 10/07/2004 | US20040198717 4-(trifluoromethyl)-7,8,9,10-tetrahydrochromeno[7,6-b]azepin-2(6H)-one and derivatives;4-(trifluoromethyl)-1,6,7,8,9,10-hexahydro-2H-azepino[3,2-g]quinolin-2-one and derivatives; useful in the treating conditions caused by androgen deficiency such as bone disorders |
| 10/07/2004 | US20040198716 Cysteine protease inhimbitors |
| 10/07/2004 | US20040198651 Secreted proteins |
| 10/07/2004 | US20040197307 Mixture of human interferons |
| 10/06/2004 | EP1464646A1 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp |
| 10/06/2004 | EP1464332A1 Combination of nicergoline and riluzole for the prevention and treatment of motoneuronal disorders |
| 10/06/2004 | EP1463799A2 Methods for the induction of professional and cytokine-producing regulatory cells |
| 10/06/2004 | EP1463756A2 Secreted proteins |
| 10/06/2004 | EP1463735A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides |
| 10/06/2004 | EP1463728A2 Fused cyclic modulators of nuclear hormone receptor function |
| 10/06/2004 | EP1463530A1 Adeno-associated virus-mediated delivery of gdnf to skeletal muscles |
| 10/06/2004 | EP1463509A1 Type 4 phosphodiesterase inhibitors and uses thereof |
| 10/06/2004 | EP1463497A2 Treating muscle wasting with selective androgen receptor modulators |
| 10/06/2004 | EP1463487A1 Liposomal delivery of vitamin e based compounds |
| 10/06/2004 | EP1379262B1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 10/06/2004 | EP1027336B1 Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors |
| 10/06/2004 | EP1018878B1 Novel indolecarboxamides, pharmaceutical compositions and methodsof inhibiting calpain |
| 10/05/2004 | US6800626 For therapy and prophylaxis of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, etc. |
| 10/05/2004 | US6800620 Contacting leukocytes, osteoclasts with an enzyme inhibitors, a 9h-purin-3h-quinazolin-4-one derivatives, treating bone-resorption disorder, antiproliferative agents treating leukemia cells |
| 10/05/2004 | US6800619 Urea heterocycliccarbonyl-substituted aspartic or glutamic acid derivatives |
| 09/30/2004 | WO2004083414A1 Monocyte-origin multipotent cell momc |
| 09/30/2004 | WO2004082693A1 Composition for administration of iron for the treatment of restless legs syndrome |
| 09/30/2004 | WO2004082581A2 Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof |
| 09/30/2004 | WO2003087333A8 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 09/30/2004 | WO2003080105A9 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof |
| 09/30/2004 | US20040194159 Cloning pigs using donor nuclei from differentiated cells |
| 09/30/2004 | US20040192916 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents |
| 09/30/2004 | US20040192886 for use in the treatment and prevention of nervous system, epileptic, pain and vision defects; neuromuscular blocking agents; local anesthetic ; analgesics; neuroprotective agents |
| 09/30/2004 | US20040192757 Reacting a 2-pyrrolidinone with alpha-keto acid; cyclization, ammonolysis , catalytic hydrogenation |
| 09/30/2004 | US20040192746 Anticancer agents; central nervous system disorders; sexual disorders; antidiabetic agents; obesity; muscular disorders; alopecia; sepsis; autoimmune disease |
| 09/30/2004 | US20040192742 Antiarthritic agents; muscular dystrophy; antiinflammatory agents; glomerulonephritis; malaria; oral diseases |
| 09/30/2004 | US20040192722 Selective iGluR5 receptor antagonists |
| 09/30/2004 | US20040192702 Heteroaryl alkyl piperazine derivatives |
| 09/30/2004 | US20040191756 Transgenic rodent for diagnosing and identifying modulator for treatment and prevention inflammatory disorders |
| 09/30/2004 | US20040191242 Method for producing a vaccine |
| 09/30/2004 | US20040191219 HSA-free formulations of interferon-beta |
| 09/30/2004 | US20040191185 Ephedrine or fenfluramine; aluminum foil coated with a thin layer of drug is heated to form vapor; which condenses to form aerosol; rapid peak plasma concentration |
| 09/30/2004 | US20040191184 Delivery of muscle relaxants through an inhalation route |
| 09/30/2004 | US20040191183 Delivery of antiemetics through an inhalation route |
| 09/30/2004 | US20040191182 Delivery of analgesics through an inhalation route |
| 09/30/2004 | US20040191181 Vaporization of diphenhydramine from solid for breathing administerig |
| 09/30/2004 | US20040191180 Breathing analgesics after vaporization for administering pain killer for headaches |
| 09/30/2004 | US20040191179 Breathing antidepressants from aerosols for administering bupropion by heating on a solid support |
| 09/30/2004 | CA2855229A1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/29/2004 | EP1461443A2 Carbohydrate-associated proteins |
| 09/29/2004 | EP1461358A1 Ifnar2 muteins, their production and use |
| 09/29/2004 | EP1461122A2 Treatment of genitourinary tract disorders |
| 09/29/2004 | EP1461086A2 Enzymatic cleavable reagents for specific delivery to disease sites |
| 09/29/2004 | EP1461071A1 Muscle transcription factors |
| 09/29/2004 | EP1461040A1 Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
| 09/29/2004 | EP1461039A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 09/29/2004 | EP1461021A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts |
| 09/29/2004 | EP1385874A4 Alpha conotoxin peptides with analgesic properties |
| 09/29/2004 | CN1533388A Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 09/29/2004 | CN1533387A 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use |
| 09/29/2004 | CN1533374A Substitutled cyclohexane-1,4-diamine derivatives |
| 09/29/2004 | CN1533283A Use of osteopontin for treatment and/or prevention of neurologic diseases |
| 09/29/2004 | CN1533281A Use of ginkeo bilobwa extracts for preparing medicine for treating sarcopenia |
| 09/29/2004 | CN1533276A Use of thiazole derivatives for preparing medicine for protecting mitochondria |
| 09/29/2004 | CN1531965A Medicinal wine for dredging channels, subduing swelling and stopping pain |
| 09/28/2004 | US6797259 Delivery of muscle relaxants through an inhalation route |
| 09/23/2004 | WO2004081040A2 Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications |
| 09/23/2004 | WO2004081039A1 Novel protein and its dna |
| 09/23/2004 | WO2004080487A1 Preventive or remedy for teeth grinding |
| 09/23/2004 | WO2004080472A1 Petasite, petasite extract and/or petasite extract fractions thereof for acute treatment of pathological conditions |
| 09/23/2004 | WO2004080436A1 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| 09/23/2004 | WO2004041258A3 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| 09/23/2004 | WO2004035011A3 Botulinum toxin dental therapies and procedures |
| 09/23/2004 | WO2003011219A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 09/23/2004 | US20040186587 Devices and methods for treating tissue |
| 09/23/2004 | US20040186299 such as 3-(3,5-dimethoxyphenyl)-2-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl}-acrylic acid; for lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes; for increasing leptin levels with no liver toxicity |
| 09/23/2004 | US20040186178 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/23/2004 | US20040186136 E.g., mono-, poly- or perdeuteriated tolperisone and eperisone; appreciably better pharmacokinetic and/or pharmacodynamic properties than the undeuterated compounds; muscular disorders; muscle relaxants (skeletal); antispasmodic agents; vasodilation |
| 09/23/2004 | US20040186134 Inhibitors of Factor Xa are useful as anticoagulants in the treatment of cardiovascular disorders associated with thromboses; e.g., 1,1-dimethylethyl 1-[1-(-2-(-3-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonylamino]-2-oxo-piperidin-1-yl)-acetyl)-pyrrolidin-2- yl-methyl]-pyrrolidin-3-yl}-methyl-carbamate |
| 09/23/2004 | US20040186130 Delivery of muscle relaxants through an inhalation route |
| 09/23/2004 | US20040186127 E.g., 7-(5-(2-(cyclohexylmethylamino)ethyl)indol-2-yl), 2-methyl-3H-imidazo(4,5-b)pyridine; antiinflammatory agents; antiproliferative agents; autoimmune diseases; reperfusion injuries; osteoporosis; bone disorders; antimetastasis agents |
| 09/23/2004 | US20040186113 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 09/23/2004 | US20040186099 Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| 09/23/2004 | US20040186045 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/23/2004 | US20040185546 enzyme inhibitor for selectin mediated binding events and methods of treating disease conditions using animal models; genetic engineering |
| 09/23/2004 | US20040185507 Isolated monoclonal antibody comprising a light and heavy chain variable of given sequence; diagnosing, treating and preventing prostate/colon cancer and renal carcinoma |
| 09/23/2004 | US20040185122 Selective COX-2 inhibition from edible plant extracts |
| 09/23/2004 | US20040185048 Modulation of IL-2- and IL-15-mediated T cell responses |
| 09/23/2004 | US20040185008 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 09/23/2004 | US20040185007 heating layers containing drugs such as benztropine, pergolide, ropinirole, amantadine and deprenyl on solid supports, to produce vapors, then condensing to aerosols which can be delivered by breathing; drug delivery method and devices |
| 09/23/2004 | US20040185006 Delivery of stimulants through an inhalation route |
| 09/23/2004 | US20040185005 Condensation aerosol as doage forms, is produced by heating a thin layer containing of dolasetron, granisetron or metoclopramide to form vapor, condense into an aerosol; fast producing peak plasma concentrations |
| 09/23/2004 | US20040185004 Delivery of erectile dysfunction drugs through an inhalation route |
| 09/23/2004 | US20040185002 condensation aerosol for delivery of a drug selected from chlordiazepoxide, betahistine, clonidine, testosterone, a conjugated estrogen, an estrogen ester, estradiol, an estradiol ester, ethinyl estradiol, an ethinyl estradiol ester and hyoscyamine |
| 09/23/2004 | US20040185001 Delivery of physiologically active compounds through an inhalation route |
| 09/23/2004 | US20040185000 Delivery of antihistamines through an inhalation route |
| 09/23/2004 | US20040184999 Delivery of anti-migraine compounds through an inhalation route |
| 09/23/2004 | US20040184998 Delivery of drug esters through an inhalation route |
| 09/23/2004 | US20040184997 volatilizing a coating of drug on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of drug and condensing the heated vapor to form condensation aerosol particles |
| 09/23/2004 | US20040184996 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 09/23/2004 | DE10311651A1 Acute treatment of pain, spasms and related disorders, e.g. migraine, asthma, colitis or depression, using petasins, furanopetasins, eremophilane lactones or Petasites extracts or their fractions |
| 09/23/2004 | CA2557737A1 Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications |